quinlash wrote: Sales are picking up and can be easily confirmed by looking over QTR reports to see the continual trend upward in sales numbers.
HEXO is still attracting investors (under-writers) such as Canacord most recently. They have strong partnerships with large companies such as Molson Coors. HEXO and Molson expanded into the U.S. in April. HEXO also has operations in Europe.
If you are looking to check the boxes as to why HEXO is likely to not only survive but thrive go ahead...
- Licensed for both Medical and Recreational Cannabis -> CHECK
- Partners with major markets players -> CHECK (Molson 2nd largest brewer in North America)
- Company with European Operations -> CHECK
- Company with exposure to U.S. Markets -> CHECK
Let's look for the other check-marks...
- Competitive Pricing vs. Blackmarket -> CHECK
- Providing accessories to support product sales -> CHECK
- Producing Cannabis 2.0 Products -> CHECK
Positive Sentiment on the Stock has appeared in the following ways:
- Strong Insider Buying -> CHECK (insides started buying last year at $6.54 and have continued to do so all year. Complete buying activity reports can be viewed through SEDAR). The same cannot be said for other major LPs out there. Canopy, ACB, Tilray and Aphria all show some level of insiders reducing or exiting their positions.
- Strong Support from Under-Writers -> CHECK. The fact that HEXO can attract an under writer is positive in it's self in this sector however we have also seen Cannacord paying over market value for shares in HEXO
- Meeting or Beating Sales Estimates -> CHECK. I believe there is only 1 QTR report estimate that HEXO missed in the last year with ever increasing percentage gains in sales Q over Q.
Investors coming into the stock see the positives and future potential of the company. With HEXO forecasting to turn positive in Calendar year 2020, that future is not far off.
Q